What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?

Drugs

Volumn 57, Issue 6, 1999, Pages 851-853

  Momméja Marin, Hervé ^a   Carbon, Claude ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG USE; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; META ANALYSIS; PENICILLIN RESISTANCE; RESPIRATORY TRACT INFECTION; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; UPPER RESPIRATORY TRACT INFECTION;

ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FLUOROQUINOLONES; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 0032966801     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957060-00002     Document Type: Article

References (11)

1. 1. Grüneberg RN, Felmingham D. Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microbiol Infect Dis 1996; 25: 169-81
2. 2. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-9
3. 3. Campos J, Roman F, Georgiou M, et al. Long term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. J Infect Dis 1996; 174: 1345-7
4. 4. Janoir C, Zeller V, Kitzis MD, et al. High level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in Par-C and Gyr-A. Antimicrob Agents Chemother 1996; 40: 2760-4
5. 5. Tankovic J, Perichon B, Duval J, et al. Contribution of mutation in Gyr-A and Par-C genes to fluoroquinolone resistance of mutants Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob Agents Chemother: 1996; 40: 2505-10
6. 6. Blum MD, Graham DJ, McCloskey CA, et al. Temafloxacin syndrome: a review of 95 cases. Clin Infect Dis 1994; 18: 946-50
7. 7. Grossman RF. How do we achieve cost-effective options in lower respiratory tract infections therapy? Chest 1998; 113 (3 Suppl.): 205S-10S
8. 8. Niederman MS, Bass JB, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-26
9. 9. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-50
10. 10. Bartlett JG, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults; guidelines for management. Clin Infect Dis 1998; 26: 811-38
11. 11. Niederman M, Traub S, Ellison WT, Trovan Pneumonia Study Group, et al. A double blind, randomized, multicenter, global study in hospitalized community acquired pneumonia trovafloxacin with ceftriaxone plus erythromycin [abstract], 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto, 377-8